Key Highlights

  • Jasper Therapeutics completes all‑stock acquisition of Kira Pharmaceuticals, forming a combined entity focused on immunologically‑driven disorders.
  • The company secures $132 million in private placement financing to fund operations through the second half of 2028.
  • Combined pipeline includes KP‑104 for paroxysmal nocturnal hemoglobinuria and briquilimab for Severe Combined Immunodeficiency.

Jasper Therapeutics has reshaped its clinical portfolio and balance sheet by completing an all‑stock acquisition of Kira Pharmaceuticals and simultaneously securing a private placement financing of approximately $132 million. The combined organization now possesses a suite of complement‑targeted and antibody‑based programs aimed at rare immune‑mediated diseases, with a cash runway expected to extend through late 2028.

Deal Structure and Financing

The transaction was executed as a stock‑for‑stock exchange, delivering Jasper common equity and non‑voting convertible preferred equity to former Kira shareholders.The proceeds, together with existing cash balances, furnish the company with sufficient liquidity to progress its development programs without immediate dilution pressures.

Pipeline Expansion and Focus

Integration of Kira’s complement‑centric assets expands Jasper’s pipeline to three lead candidates. KP‑104, a dual‑complement inhibitor, is being evaluated for paroxysmal nocturnal hemoglobinuria and select renal indications, with phase‑2 data anticipated later in 2026. Briquilimab, an anti‑KIT antibody, targets Severe Combined Immunodeficiency and is preparing for an early regulatory interaction with the FDA.

Strategic Rationale and Market Positioning

The merger reflects a strategic effort to combine complementary scientific expertise in complement biology with Jasper’s antibody development platform, addressing significant unmet needs in immunology. The $132 million financing bolsters the company’s runway, enabling it to meet key milestones such as the KP‑104 phase‑2 readout and regulatory engagements for briquilimab. By securing capital through 2028, Jasper aims to limit the frequency of external financing rounds that have pressured peer biotech firms, thereby reducing execution risk.

The out‑licensing arrangement further streamlines the pipeline, concentrating resources on candidates with the greatest commercial promise. The regulatory dialogue for briquilimab, expected in the near term, will clarify the pathway toward a biologics license application. While the financing provides a solid liquidity cushion, the company’s ability to achieve these clinical and regulatory milestones will be key for future partnership opportunities and valuation.

Potential challenges encompass competitive pressures within the complement‑targeted space and the inherent uncertainties of early‑stage development programs. Based on the company’s disclosure filed 16 July 2026.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.